Management Impact of Metachronous Oligometastatic Disease Identified on 18F-Fluciclovine (Axumin ™) PET/CT in Biochemically Recurrent Prostate Cancer

ConclusionThe incidence rate of oligometastatic disease in men with first BCR of PCA undergoing18F-fluciclovine PET/CT for imaging evaluation of BCR was 23.6% in our eligible patient population. There was no significant association between serum PSA level and the number of oligometastases. Treatment management was affected in 57.1% of patients with oligometastases.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research